News | October 24, 2022
Lupin launches Paliperidone Extended-Release Tablets in US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
The product will be manufactured at Lupin's facility in Nagpur, India.
The inspection of the facility was conducted from August 16-19, 2022.
Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Subscribe To Our Newsletter & Stay Updated
